Atrium Therapeutics (RNA) Director Sarah Boyce Withholds 126,418 Shares

What Happened
Sarah Boyce, a director of Atrium Therapeutics, had 126,418 shares withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units. The shares were valued at $8.95 each, totaling $1,131,441. This was a tax-withholding disposition (code F), not an open-market sale.

Key Details

• Transaction date and price: 2026-09-18; 126,418 shares withheld at $8.95 per share (total $1,131,441).
• Transaction code: F (shares withheld to satisfy tax withholding on vesting).
• Footnote: F1 — issuer withheld shares to cover tax withholding on RSU vesting.
• Filing date: Form 4 filed 2026-09-22 (filed on the second business day after the Sep 18 transaction, which is timely).
• Shares owned after transaction: Not specified in the summary data provided.

Context
Share withholding to cover taxes on vested restricted stock units is a routine administrative action and should not be interpreted the same as an intentional market sale by the insider. It reduces the insider’s outstanding shares because the company retains shares to pay taxes rather than the insider selling shares on the open market.